What is Zacks Research's Estimate for ESPR FY2027 Earnings?

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at Zacks Research issued their FY2027 EPS estimates for shares of Esperion Therapeutics in a report released on Tuesday, March 25th. Zacks Research analyst K. Das expects that the biopharmaceutical company will post earnings per share of $0.06 for the year. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share.

Other equities research analysts also recently issued reports about the company. Needham & Company LLC reissued a "buy" rating and issued a $6.00 price objective on shares of Esperion Therapeutics in a report on Friday, December 13th. JMP Securities reaffirmed a "market outperform" rating and set a $4.00 price objective (down from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. Cantor Fitzgerald started coverage on Esperion Therapeutics in a report on Tuesday, December 17th. They issued an "overweight" rating and a $8.00 target price on the stock. The Goldman Sachs Group started coverage on Esperion Therapeutics in a research note on Wednesday, December 18th. They set a "neutral" rating and a $4.00 price target for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research note on Thursday, March 20th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $6.75.

Remove Ads

Esperion Therapeutics Stock Performance

Shares of ESPR stock traded down $0.05 during mid-day trading on Thursday, hitting $1.46. 2,856,044 shares of the stock were exchanged, compared to its average volume of 4,190,596. The stock's fifty day simple moving average is $1.78 and its two-hundred day simple moving average is $2.07. Esperion Therapeutics has a 12-month low of $1.42 and a 12-month high of $3.94. The stock has a market capitalization of $287.87 million, a price-to-earnings ratio of -2.27 and a beta of 1.04.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ESPR. Cibc World Markets Corp acquired a new stake in Esperion Therapeutics in the fourth quarter valued at $39,000. SJS Investment Consulting Inc. acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at about $55,000. Crestline Management LP purchased a new stake in Esperion Therapeutics during the fourth quarter worth about $63,000. SLT Holdings LLC acquired a new position in Esperion Therapeutics during the fourth quarter worth about $66,000. Finally, Foundations Investment Advisors LLC increased its holdings in Esperion Therapeutics by 48.6% in the fourth quarter. Foundations Investment Advisors LLC now owns 30,172 shares of the biopharmaceutical company's stock valued at $66,000 after buying an additional 9,872 shares in the last quarter. Institutional investors and hedge funds own 47.39% of the company's stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.